Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Denmark
Clinical trial register · European Union · CTIS

Clinical Trials in Denmark, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2557 most recently authorised of 12561 total CTIS records — a stated recency window, not the full historical archive. Synced 06 Oct 2026, 03:17 UTC
2557
Shown in this register
most recently authorised
12,561
Total on CTIS
full historical archive
776
Phase III
within the shown window
Top member states
Spain 1059 France 917 Germany 897 Italy 756 Poland 605 Netherlands 555
Narrow the registerReset
Phase
Phase I 573 Phase I/II 216 Phase II 728 Phase III 776 Phase IV 264
Lead sponsor
AstraZeneca AB 66 Merck Sharp & Dohme LLC 50 Pfizer Inc. 48 Assistance Publique Hopitaux De Paris 48 Novartis Pharma AG 43
Member state
Spain 1059 France 917 Germany 897 Italy 756 Poland 605 Netherlands 555 Belgium 451 Czechia 340
All 28 states

Trials with a site in Denmark

331 of 2557 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase III
A Phase III Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin compared with Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve Patients
2026-525642-30-00Hypercholesterolaemia
DrugsAZD0780·Rosuvastatin
AstraZeneca AB
Nutritional and Metabolic Diseases
Denmark
05/10/2026
Phase III
Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - the PREDICT Study
2026-527337-63-00Bacterial urinary tract infections and bloodstream infectio…
DrugPivmecillinam
Region Hovedstaden
Bacterial Infections and Mycoses
Denmark
05/10/2026
Phase II
LIGHTBEAM-U01 Substudy 01E: A Phase 2 Substudy to Evaluate the Safety and Efficacy of Belzutifan in Participants With Solid Tumors
2025-524515-37-00Neoplasm malignant
DrugBelzutifan
Merck Sharp & Dohme LLC
Neoplasms
Belgium, Denmark
05/10/2026
Phase II
SEMAGONA: A randomized four-arm parallel group double-blind double dummy 52-week clinical trial comparing the effects of s.c. Semaglutide 2.4 mg once-weekly, i.m. testosterone undecanoate 1,000 mg every 13th week, combination of s.c. Semaglutide 2.4 mg once-weekly and i.m. testosterone undecanoate 1,000 mg every 13th week, and placebo on body composition and hypogonadal symptoms in men with obesity-associated functional hypogonadism
2026-527373-11-00Functional hypogonadism
DrugsNebido·Semaglutide
Region Hovedstaden
Hormonal diseases
Denmark
30/09/2026
Phase III
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer’s Disease
2025-524314-29-00Cognitively Unimpaired Individuals at Risk for Progression …
DrugTrontinemab
F. Hoffmann-La Roche AG
Nervous System Diseases
Spain, Denmark
29/09/2026
Phase II
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD
2026-525216-34-00Chronic Obstructive Pulmonary Disease (COPD) exacerbations
Expedition Therapeutics Inc.
Respiratory Tract Diseases
Italy, Germany, Spain, Poland, Czechia, Romania, Hungary, Denmark, Bulgaria
29/09/2026
Phase III
A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants with Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)
2025-522954-37-00Peripheral Artery Disease
DrugsAmrecibart·Cenvacibart·Rivaroxaban
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Spain, Slovakia, Hungary, Czechia, Romania, Estonia, Austria, France, Belgium, Sweden, Italy, Latvia, Poland, Bulgaria, Greece, Germany, Denmark, Lithuania, Netherlands
29/09/2026
Phase I
A prospective, open-label, single-arm, multicenter pharmacokinetic study evaluating the placental transfer of dapirolizumab pegol to the infant(s) from pregnant study participants with active systemic lupus erythematosus who are administered dapirolizumab pegol
2025-524595-37-00Systemic lupus erythematosus (SLE)
DrugsDiphenhydramine·Epinephrine·Paracetamol
UCB Biopharma
Immune system processes
Greece, Italy, Netherlands, Austria, Belgium, Sweden, Spain, Denmark, Germany
28/09/2026
Phase III
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
2026-526139-20-00Symptomatic genetic and familial dilated cardiomyopathy.
DrugDanicamtiv
Kardigan Inc.
Cardiovascular Diseases
Poland, Sweden, Belgium, France, Spain, Hungary, Denmark, Italy, Netherlands
28/09/2026
Phase I
A study to investigate safety and effectiveness of REM0045392 compared with placebo in healthy elderly participants and participants with Alzheimer’s disease
2026-527490-11-00Alzheimer's disease
reMYND
Nervous System Diseases
Denmark
28/09/2026
Phase III
A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients with Generalized Myasthenia Gravis (EMERGE)
2026-525298-38-00generalized Myasthenia gravis
DrugClaseprubart
Dianthus Therapeutics Inc.
Immune System Diseases
Czechia, Portugal, Austria, Bulgaria, Germany, France, Latvia, Poland, Italy, Spain, Denmark
28/09/2026
Phase III
A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Face and Neck Atopic Dermatitis
2025-525133-31-00Face and Neck Atopic Dermatitis
DrugLebrikizumab
Almirall S.A.
Skin and Connective Tissue Diseases
Poland, Germany, Portugal, France, Spain, Denmark
22/09/2026
Phase II
A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients with Fibrostenosing Crohn’s Disease
2026-525197-19-00Fibrostenosing Crohn’s Disease
DrugOntunisertib
Agomab Spain S.L.U.
Digestive System Diseases
France, Germany, Poland, Spain, Czechia, Denmark, Austria, Italy, Belgium, Netherlands
21/09/2026
Phase III
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight
2026-525408-82-00Chronic Weight Management
DrugMaridebart cafraglutide
Amgen Inc.
Nutritional and Metabolic Diseases
Czechia, Spain, Poland, Denmark, Germany, Italy, Belgium, Finland
21/09/2026
Phase III
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants with Obesity or Overweight with at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus
2025-523295-23-00Obesity or Overweight Weight-Related Comorbidity with/witho…
DrugLenbelintide
AstraZeneca AB
Nutritional and Metabolic Diseases
Sweden, Denmark
21/09/2026
Phase III
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy
2025-523362-25-00Neoplasms, Endometrial
DrugsDoxorubicin·Paclitaxel
Glaxosmithkline Research & Development Limited
Neoplasms
Denmark, Netherlands, Italy, Spain, France, Portugal, Greece, Poland, Germany, Belgium, Norway, Czechia
21/09/2026
Phase III
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with standard of care in participants with platinum- resistant ovarian cancer.
2025-523361-25-00Ovarian Neoplasms
DrugsDoxorubicin·Gemcitabine·Paclitaxel·Bevacizumab
Glaxosmithkline Research & Development Limited
Neoplasms
Denmark, Austria, France, Sweden, Finland, Netherlands, Norway, Czechia, Belgium, Greece, Italy, Germany, Spain
21/09/2026
Phase IV
A Pragmatic Randomized Trial to Evaluate the Relative Effectiveness of Abrysvo® Revaccination Versus a Single Primary Dose for Preventing RSV-associated Lower Respiratory Tract Disease in Immunocompromised Adults (DAN-RSV IC REVAX)
2026-527536-14-00Respiratory syncytial virus infection
DrugVaxzevria
Region Hovedstaden, Pfizer Inc.
Virus Diseases
Denmark
21/09/2026
Phase III
A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults with Idiopathic Pulmonary Fibrosis (SURPASS-IPF)
2025-524493-42-00Idiopathic Pulmonary Fibrosis
DrugsDeupirfenidone·Pirfenidone
Puretech Lyt 100 Inc.
Respiratory Tract Diseases
Greece, Italy, Czechia, France, Portugal, Denmark, Spain, Poland, Germany, Romania, Belgium, Netherlands
18/09/2026
Phase III
A Multicentre, Parallel-Group, Observer-Blind, Randomised, Placebo-Controlled, Pivotal Trial Investigating the Safety and Immunogenicity of Group B Streptococcus Vaccine (GBS-NN/NN2) in Pregnant Women and Infants Born to Pregnant Women Vaccinated During Pregnancy
2026-525385-21-00Prevention of Group B streptoccoccus infection
Minervax ApS
Bacterial Infections and Mycoses
Czechia, Belgium, Denmark, Spain
18/09/2026
Phase II
The Role of Serotonin 4 Receptor Agonism in Regulating Mood and Cognition in Depression in women (RECAP-D)
2026-526685-25-00Major depressive disorder
DrugsPrucalopride·Sertraline
Region Hovedstaden
Mental Disorders
Denmark
17/09/2026
Phase III
Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either overweight or obesity (AMBIENCE)
2026-525182-53-00Atherosclerotic cardiovascular disease and either overweigh…
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Czechia, Greece, France, Italy, Germany, Spain, Poland, Netherlands, Bulgaria
16/09/2026
Phase II
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
2025-524439-38-00Non Small Cell Lung Cancer (NSCLC)
DrugDurvalumab
Oslo Universitetssykehus HF
Respiratory Tract Diseases
Sweden, Norway, Denmark
16/09/2026
Phase II
J2S-MC-GZMV: A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
2026-525480-41-00Pulmonary Disease, Chronic Obstructive
DrugBrenipatide
Eli Lilly & Co.
Respiratory Tract Diseases
Denmark, France, Romania, Czechia, Poland, Hungary, Germany, Austria
15/09/2026
Phase IV
POISON – Perioperative Safety and Effective Opioid Dosing in Chronic Opioid Use – a Randomized Clinical Study
2026-526719-13-00Opioid dependent chronic pain
DrugOxycodone
Region Hovedstaden
Anesthesia and Analgesia
Denmark
08/09/2026
Phase II
SemenGlutide: A randomized double-blinded, placebo-controlled, single-center, clinical trial comparing the effects of s.c. Semaglutide 2.4 mg once-weekly versus placebo on sperm concentration in overweight infertile men
2026-527538-29-00Infertility, overweight
DrugSemaglutide
Region Hovedstaden
Male Urogenital Diseases
Denmark
08/09/2026
Phase II
Effects of semaglutide as add-on therapy to sulfonylurea on plasma glucose in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SEMA)
2025-523414-89-00Maturity-onset diabetes of the young type 3 (HNF1A-MODY), M…
DrugSemaglutide
Steno Diabetes Center Copenhagen
Hormonal diseases
Denmark
08/09/2026
Phase III
Zoledronic acid as prophylaxis against glucocorticoid-induced osteoporosis in lymphoma
2026-527220-27-00Large B-cell lymphomas, transformations of indolent B-cell …
DrugZoledronic Acid
Region Nordjylland
Neoplasms
Denmark
07/09/2026
Phase I
A Study of RO7806767 as Single Agent and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
2026-525215-13-00Advanced Solid Tumors
F. Hoffmann-La Roche AG
Neoplasms
Spain, Poland, Romania, Hungary, Germany, Italy, Belgium, Netherlands, Denmark, France
07/09/2026
Phase IV
Reduced-dose versus full-dose systemic thrombolysis for high-risk pulmonary embolism: a multicentre, randomised, open-label, blinded-endpoint trial
2024-515904-37-00Pulmonary embolism
DrugAlteplase
Vaestra Goetalandsregionen, University Of Gothenburg
Cardiovascular Diseases
Denmark, Sweden, Norway
02/09/2026
Phase III
A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy
2026-525913-30-00Immune system diseases
DrugsBelumosudil·Ixazomib·Imatinib·Sirolimus
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, Hungary, Sweden, Lithuania, Croatia, Netherlands, Slovakia, Poland, Austria, Norway, France, Italy, Bulgaria, Spain, Germany, Romania, Slovenia, Estonia, Portugal, Greece, Denmark
02/09/2026
Phase III
Antibiotikapenetration og vævsrespons ved infektion og rekonstruktiv kirurgi i hoved-hals regionen
2026-526995-22-00Treatment and prevention of post operative infections
DrugsDicloxacillin·Cefuroxime·Amoxicillin
Region Midtjylland
Bacterial Infections and Mycoses
Denmark
02/09/2026
Phase II
Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
2025-524748-37-00Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
DrugCenegermin
Dompe' Farmaceutici S.p.A.
Eye Diseases
Denmark, Italy, Germany, Hungary, Netherlands, Spain, Belgium, France, Portugal
01/09/2026
Phase III
A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).
2025-524014-29-00Newly Diagnosed Multiple Myeloma
DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab
AstraZeneca AB
Neoplasms
Poland, Italy, Denmark, France, Sweden, Germany, Spain
01/09/2026
Phase II
HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma
2025-524230-25-00Diffuse large B-cell lymphoma (DLBCL)
DrugsEpcoritamab·Rituximab
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Hemic and Lymphatic Diseases
Czechia, Denmark, Croatia, Spain, Sweden, Finland, Portugal, Ireland, Netherlands, Belgium, Norway
31/08/2026
Phase II
Targeting IL-13 in Bullous Pemphigoid: An Investigator-Initiated, Prospective, Multicenter, Proof-of-Concept, Open-Label Pilot Study of Lebrikizumab
2026-525685-22-00Bullous pemphigoid
DrugLebrikizumab
Region Midtjylland, Region Sjaelland
Immune System Diseases
Denmark
31/08/2026
Phase II
Paediatric sarcoma, hybrid imaging & FAPI – Raising the diagnostic standard for paediatric sarcoma patients combining novel radiotracer FAPI and whole-body PET/MRI
2025-524874-41-00Paediatric sarcoma
Drug[68Ga]Ga-FAPI-46
Rigshospitalet
Diagnosis
Denmark
28/08/2026
Phase IV
S-KETamine vs. propofol for prehospital sedation of patients with severe Acute Brain Injury: The KETABI randomised trial
2026-525588-41-00traumatic brain injury, subarachnoid haemorrhage, intracere…
DrugPropofol
Region Hovedstaden
Pathological Conditions, Signs and Symptoms
Denmark
27/08/2026
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis
2025-521901-42-00Idiopathic Pulmonary Fibrosis (IPF)
Contineum Therapeutics Inc.
Respiratory Tract Diseases
Italy, Belgium, Denmark, Austria, Greece, Germany, France, Netherlands, Portugal, Poland, Spain
26/08/2026
Phase II
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers
2025-524130-26-00Gastrointestinal Cancers
DrugPegfilgrastim
Genmab A/S
Neoplasms
Italy, Belgium, France, Spain, Denmark, Netherlands, Germany
26/08/2026
Phase IV
Piperacillin/tazobactam or ampicillin and gentamicin for empirical treatment of community acquired infection: A randomised clinical trial (PAGER)
2026-526131-20-00Urosepsis, Infection of unknown origin, Pyelonephritis, Cys…
DrugsAmpicillin·Gentamicin
Region Hovedstaden
Bacterial Infections and Mycoses
Denmark
25/08/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)
2025-524928-21-00Pancreatic Adenocarcinoma
DrugRMC-9805
Revolution Medicines Inc.
Neoplasms
Sweden, Spain, France, Poland, Italy, Norway, Belgium, Germany, Czechia, Austria, Netherlands, Denmark
24/08/2026
Phase IV
Adalimumab Treatment for Patients with Hidradenitis Suppurativa at high risk of Progressing to Severe Disease: An Unblinded Randomized, Controlled Trial
2025-522505-37-00Hidradenitis suppurativa
DrugsDoxycycline·Adalimumab
Gentofte Hospital
Skin and Connective Tissue Diseases
Denmark
24/08/2026
Phase II
Èn dosis intravenøs penicillin som tillæg til peroral penicillin i behandlingen af akut tonsillitis, peritonsillær phlegmone og peritonsillær absces – et randomiseret, dobbeltblindet, placebo-kontrolleret studie
2026-526903-31-00Tonsillitis
DrugBenzylpenicillin
Region Midtjylland
Bacterial Infections and Mycoses
Denmark
21/08/2026
Phase IV
An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
2026-526068-19-00Transthyretin Amyloidosis
DrugAcoramidis
Eidos Therapeutics Inc.
Cardiovascular Diseases
Spain, Denmark
20/08/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)
2025-525102-38-00Elevated lipoprotein(a)
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Netherlands, Denmark, Germany, Spain
18/08/2026
Phase III
Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)
2026-525513-31-00Small-cell lung cancer, limited stage
DrugDurvalumab
Norges Teknisk-Naturvitenskapelige Universitet NTNU
Neoplasms
Denmark, Finland, Estonia, Germany, Lithuania, Sweden, Norway, Netherlands
17/08/2026
Phase II
[⁶⁸Ga]Ga-HKG301 PET/CT for staging and restaging patients with primary breast cancer: a phase II study (FAPILOUS)
2025-521324-29-00Primary breast cancer
Odense University Hospital
Neoplasms
Denmark
14/08/2026
Phase II
A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA) (Breakfree-AiCE)
2025-524993-41-00Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemol…
Celgene Corp.
Immune System Diseases
Germany, Denmark
10/08/2026
Phase III
Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity
2025-524626-18-00Overweight and obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands, Belgium, Greece, Poland, Spain, Denmark, France, Bulgaria, Sweden
10/08/2026
Phase IV
The RHINOME study
2026-527032-14-00Severe asthma
Region Hovedstaden
Respiratory Tract Diseases
Denmark
10/08/2026
Phase II
An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma
2025-523472-23-01Cutaneous T-cell lymphoma (CTCL) Mycosis fungoides
DrugDelgocitinib
Region Midtjylland
Therapeutics
Denmark
10/08/2026
Phase III
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs
2025-523333-26-00Graves' Disease (GD)
Argenx
Hormonal diseases
Italy, Czechia, Spain, Denmark, Belgium, Romania, Latvia, France, Germany, Greece, Sweden, Poland, Lithuania, Bulgaria
07/08/2026
Phase IV
A Phase 4, Pragmatic, Randomized Trial to Evaluate the Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years (DAN-COMBO)
2026-526720-49-00Influenza infection, SARS-CoV-2 infection
Gentofte Hospital, Moderna Inc.
Virus Diseases
Denmark, Spain
07/08/2026
Phase III
ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment
2025-523307-29-00Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hyper…
DrugBenralizumab
AstraZeneca AB
Respiratory Tract Diseases
Denmark, Belgium, France, Italy, Netherlands, Austria, Poland
04/08/2026
Phase II
A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)
2025-525016-41-00Idiopathic Pulmonary Fibrosis
AstraZeneca AB
Respiratory Tract Diseases
Poland, Hungary, Netherlands, Germany, Spain, Greece, Bulgaria, Italy, France, Denmark
04/08/2026
Phase III
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)
2025-523940-12-00type 2 diabetes mellitus
AstraZeneca AB
Nutritional and Metabolic Diseases
Germany, Bulgaria, Spain, Denmark
03/08/2026
Phase III
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared with Elecoglipron Alone and Dapagliflozin Alone, in Adults with Type 2 Diabetes Mellitus (Eluminate-5)
2025-523941-81-00type 2 diabetes mellitus
AstraZeneca AB
Nutritional and Metabolic Diseases
Slovakia, Poland, Czechia, Germany, Hungary, Greece, Denmark
03/08/2026
Phase III
A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)
2025-523884-39-00Systemic sclerosis
DrugNerandomilast
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Skin and Connective Tissue Diseases
Denmark, Hungary, Sweden, Netherlands, Germany, Belgium, France, Greece, Norway, Finland, Czechia, Portugal, Bulgaria, Spain, Austria, Romania, Croatia, Poland, Estonia, Italy, Lithuania
03/08/2026
Phase III
A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis
2026-525923-26-00Moderately to Severely Active Ulcerative Colitis
DrugsJNJ-78934804·Guselkumab
Janssen Cilag International
Immune System Diseases
France, Bulgaria, Romania, Slovakia, Norway, Denmark, Greece, Italy, Austria, Poland, Netherlands, Czechia, Germany, Belgium, Spain, Hungary, Portugal
03/08/2026
Phase II
Botulinum toxin A in the Treatment of Chronic Postsurgical Pain in Lung Cancer Patients: A feasibility study
2026-525669-33-00Chronic postsurgical pain (CPSP)
DrugXeomin
Aalborg University Hospital
Therapeutics
Denmark
01/08/2026
Phase II
The Danish Anorexia Nervosa Psilocybin RCT (DANP-RCT). A Randomised, Active-Placebo-Controlled, Triple-blind, Superiority Study of Psilocybin-Assisted Acceptance and Commitment Therapy (ACT) in the Treatment of Treatment-resistant Anorexia Nervosa.
2025-524939-39-02Anorexia nervosa
DrugPsilocybin
Slagelse Hospital
Mental Disorders
Denmark
01/08/2026
Phase I/II
A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3
2025-525111-17-00Spinocerebellar ataxia type 3
Institut De Recherches Internationales Servier IRIS
Nervous System Diseases
France, Denmark, Spain, Portugal
30/07/2026
Phase III
A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1)
2023-510098-33-01Follicular Lymphoma
DrugsSurovatamig·Bendamustine·Vincristine·Doxorubicin
AstraZeneca AB
Neoplasms
Denmark, Germany
29/07/2026
Phase I
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination with Bevacizumab in Adult Participants with Ovarian Cancer
2025-522209-40-00Ovarian Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Portugal, Denmark, Spain, France
27/07/2026
Phase II
A randomised active-controlled trial to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation
2026-525417-31-00non-valvular atrial fibrillation
DrugsRBD4059·Apixaban
Ribocure Pharmaceuticals AB
Cardiovascular Diseases
Norway, Denmark, Poland, Sweden
24/07/2026
Phase III
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)
2025-523994-41-00Chronic kidney disease (CKD) in adults, with specified rang…
DrugsElecoglipron·Dapagliflozin
AstraZeneca AB
Cardiovascular Diseases
Czechia, Italy, Hungary, Romania, Bulgaria, Sweden, Denmark, Poland, Spain, Norway, Finland, Greece, France, Germany
24/07/2026
Phase III
A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis
2026-525242-29-00Primary Sclerosing Cholangitis
DrugElafibranor
Ipsen Bioscience Inc.
Digestive System Diseases
Spain, Sweden, Germany, Romania, Finland, Portugal, Austria, Italy, Denmark, Czechia, France, Netherlands, Poland, Belgium, Norway
21/07/2026
Phase III
A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease
2025-522227-99-00Huntington’s Disease
DrugVotoplam
Novartis Pharma AG
Nervous System Diseases
Norway, Poland, Spain, Sweden, Bulgaria, Netherlands, Finland, Portugal, Austria, Italy, Greece, Ireland, Czechia, France, Romania, Belgium, Germany, Denmark, Slovakia, Hungary
20/07/2026
Phase III
Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Subjects (age 12 to <18 years) with Homozygous Familial Hypercholesterolemia (SPRUCE)
2025-523662-24-00Homozygous Familial Hypercholesterolemia (HoFH)
DrugZodasiran
Arrowhead Pharmaceuticals Inc.
Cardiovascular Diseases
Netherlands, Denmark, Norway, Sweden, Poland
20/07/2026
Phase III
A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
2025-524648-37-00Metastatic colorectal cancer
Merck Healthcare KGaA
Neoplasms
Belgium, Germany, France, Denmark, Poland, Spain, Netherlands, Italy, Austria
14/07/2026
Phase III
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma
2025-525088-34-00Metastatic Pancreatic Adenocarcinoma
Revolution Medicines Inc.
Digestive System Diseases
Poland, Belgium, Norway, Sweden, Austria, Germany, Denmark, Netherlands, France, Italy, Spain
14/07/2026
Phase IV
Efficacy of oral bicarbonate versus placebo on the risk of assisted delivery in nulliparous women with prolonged labour (ProLabour): protocol fora randomized controlled trial
2026-525682-45-00Prolonged labour
Region Hovedstaden
Female Urogenital Diseases and Pregnancy Complications
Denmark
14/07/2026
Phase II
Inducing durable immunological control of HIV-1 through administration of long-acting broadly neutralizing antibodies and low-dose anti-PD-1 – a randomized, double-blinded, placebo-controlled trial (the IDUNN trial)
2025-523725-17-00HIV-1 disease
DrugsTeropavimab·Zinlirvimab·Nivolumab
Region Midtjylland
Immune System Diseases
Sweden, Norway, Denmark, Iceland
13/07/2026
Phase I
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
2026-525234-39-00Relapsed or Refractory acute myeloid leukemia, Relapsed or …
Janssen Cilag International
Neoplasms
France, Spain, Germany, Denmark, Belgium
13/07/2026
Phase I/II
EXUROC Bladder Target - A phase Ib/ll study to determine the safety, tolerability, and efficacy of LP-184 treatment in patients with advanced/metastatic urothelial carcinoma
2026-525808-94-00Oncology
Region Hovedstaden
Neoplasms
Denmark
10/07/2026
Phase III
Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)
2023-505575-69-01Osteosarcoma
DrugCabozantinib
Institut Gustave Roussy
Neoplasms
Sweden, Poland, Denmark, Finland, Netherlands, Italy, France, Spain
08/07/2026
Phase III
A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)
2025-523369-32-00Fibrosing interstitial lung disease
DrugNerandomilast
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Respiratory Tract Diseases
Belgium, Greece, Germany, France, Finland, Spain, Czechia, Poland, Italy, Netherlands, Denmark, Portugal
07/07/2026
Phase III
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy
2025-524028-23-00Multiple Myeloma
DrugsCevostamab·Elotuzumab·Carfilzomib·Pomalidomide
F. Hoffmann-La Roche AG
Neoplasms
France, Germany, Italy, Greece, Denmark, Czechia, Spain, Poland
07/07/2026
Phase III
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype
2024-518016-39-00Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Denmark, Sweden, Poland, Estonia, Portugal, Latvia, Spain, Hungary, Germany, Finland, Italy, Belgium, France
06/07/2026
Phase IV
Efficacy, Safety, and Patient Satisfaction of Patient-Controlled Remimazolam Sedation in Outpatient Colonoscopy: A randomized controlled trial.
2026-525809-13-00The trial will study sedation related to colonoscopy, there…
DrugsAlfentanil·Remimazolam·Midazolam
Region Hovedstaden
Digestive System Diseases
Denmark
06/07/2026
Phase III
The RELEASE Trial: Reconsidering Long-Term Aspirin in the Elderly in Secondary Prevention of Cardiovascular Disease
2026-525442-30-00Ischemic heart disease/Chronic coronary syndrome (Myocardia…
Odense University Hospital
Cardiovascular Diseases
Denmark
06/07/2026
Phase IV
Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference
2026-525221-21-01Rheumatoid arthritis
DrugsCertolizumab Pegol·Sulfasalazine·Golimumab·Leflunomide
Aalborg University Hospital, Aalborg University Hospital
Musculoskeletal Diseases
Denmark
06/07/2026
Phase II
The Acute and Long-term Impact of Support in Psilocybin Therapy for Depression: The Psilocybin Setting Trial (PSISET)
2025-522961-31-01Depression
DrugPsilocybin
Kobenhavns Universitet, Koebenhavns Universitet
Mental Disorders
Denmark
03/07/2026
Phase I
Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial - The CALCIFER Trial
2026-526388-39-00Bladder cancer, Bladder tumors, Urothelial cancer, Urotheli…
Region Sjaelland
Female Urogenital Diseases and Pregnancy Complications
Denmark
03/07/2026
Phase I/II
The headache- and migraine-inducing effects of apremilast in women with migraine without aura
2026-525987-16-00Migraine without aura
DrugApremilast
Syddansk Universitet (University of Southern Denmark)
Nervous System Diseases
Denmark
01/07/2026
Phase III
A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)
2025-522167-15-00Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
Genmab A/S
Neoplasms
Finland, Belgium, Hungary, France, Denmark, Austria, Germany, Italy, Spain, Czechia, Norway, Poland
01/07/2026
Phase III
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
2025-521769-29-00Pulmonary Hypertension Associated with Interstitial Lung Di…
DrugTreprostinil Palmitil
Insmed Inc.
Respiratory Tract Diseases
Greece, France, Italy, Belgium, Denmark, Germany, Poland, Czechia, Portugal, Austria, Spain, Romania
30/06/2026
Phase III
A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma
2025-524397-42-00Participants with relapsed HRNB and participants with HRNB…
DrugsTemozolomide·Irinotecan
Renaissance Pharma Limited
Nervous System Diseases
France, Spain, Denmark, Ireland, Germany
30/06/2026
Phase IV
Unprescribing the Pill to Reassess Symptom and Cognitive Recovery in Depression (UNPRESCRIB-D)
2026-526314-90-00Major Depressive Disorder
DrugsSertraline·Duloxetine
Region Hovedstaden
Mental Disorders
Denmark
29/06/2026
Phase III
Self-Assessment Method for Statin side-effects Or Nocebo 2
2025-524955-30-01Cardiovascular diseases
DrugRosuvastatin
Copenhagen University Hospital, Region Hovedstaden
Musculoskeletal Diseases
Denmark
28/06/2026
Phase III
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00Pancreatic Ductal Adenocarcinoma
DrugsINCB161734·Fluorouracil·Irinotecan·Oxaliplatin
Incyte Corp.
Neoplasms
Poland, Italy, Netherlands, Sweden, Denmark, Finland, Spain, France, Germany, Belgium, Norway, Austria
26/06/2026
Phase IV
A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol
2026-525658-13-00Haematological diseases; any disorder that primarily affect…
DrugsLinvoseltamab·Talquetamab·Elranatamab·Teclistamab
Region Hovedstaden
Hemic and Lymphatic Diseases
Denmark
25/06/2026
Phase III
Evaluating the effect of inhaled levodopa (Inbrija®) for early morning off in Parkinson’s disease
2026-526465-18-00parkinson's disease
DrugLevodopa
Region Hovedstaden
Nervous System Diseases
Denmark
25/06/2026
Phase II
A Phase IIb, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50).
2025-524481-15-00Heriditary spastic paraplegia (SPG50)
DrugMelpida
Rigshospitalet, Elpida Therapeutics SPC
Nervous System Diseases
Denmark
23/06/2026
Phase III
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis
2025-524322-18-00Non-active Secondary Progressive Multiple Sclerosis (SPMS)
DrugOrelabrutinib
Zenas Biopharma (USA) LLC
Nervous System Diseases
Germany, Bulgaria, Netherlands, Sweden, Portugal, Croatia, Italy, Austria, Spain, Poland, France, Denmark, Hungary, Romania, Estonia, Slovakia, Belgium, Czechia, Norway, Lithuania, Greece, Slovenia
22/06/2026
Phase II
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)
2025-522951-24-00Osteogenesis Imperfecta
DrugAGA2115
Angitia Inc. Ltd.
Musculoskeletal Diseases
Netherlands, France, Denmark
22/06/2026
Phase II
A Phase 2, Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of LTG-321 in Patients with Osteoarthritis of the Knee
2026-525966-22-00Osteoarthritis of the knee
Latigo Biotherapeutics Inc.
Musculoskeletal Diseases
Denmark
22/06/2026
Phase I
A phase 1 first-in-human study of a phenylalanine-binding polymer (phelimin) in healthy volunteers and adult, classical PKU patients
2024-519121-38-01Phenylketonuria
Mipsalus ApS
Nutritional and Metabolic Diseases
Denmark
17/06/2026
Phase III
IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis
2025-522373-10-00Progressive pulmonary fibrosis and Idiopathic pulmonary fib…
DrugAdmilparant
Bristol-Myers Squibb Services Unlimited Company
Respiratory Tract Diseases
Finland, Portugal, Hungary, Ireland, Poland, Greece, France, Belgium, Denmark, Italy, Spain, Netherlands, Austria, Germany
17/06/2026
Phase I
A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
2025-523130-11-00Advanced solid tumors, Hematological malignancies
Incyte Corp.
Neoplasms
Italy, Belgium, Denmark
16/06/2026
Phase III
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)
2025-524371-23-00Limb Girdle Muscular Dystrophy (LGMD) Type 2I
DrugRibitol
ML Bio Solutions Inc.
Musculoskeletal Diseases
Germany, Denmark, Netherlands, Italy, Norway
15/06/2026
Phase II
A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy
2025-522114-23-00Multiple myeloma (RRMM)
Odense University Hospital
Neoplasms
Finland, Denmark, Estonia, Norway
15/06/2026
Phase III
A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
2025-522267-15-00​Relapsed/refractory B-cell Acute Lymphoblastic Leukemia​
DrugsMK-1045·Blinatumomab·Tocilizumab
Merck Sharp & Dohme LLC
Neoplasms
Greece, Netherlands, Sweden, France, Italy, Spain, Denmark
12/06/2026
Phase IV
BEAT Fatigue – Benefit of Elevated Administration of Thiamine for Fatigue in Rheumatoid Arthritis: A randomized, double-blind, placebo-controlled trial
2024-519268-41-00Fatigue in rheumatoid arthritis patients
Odense University Hospital
Musculoskeletal Diseases
Denmark
12/06/2026
Phase I
A clinical trial to learn about the effects of JFI447 and how it shows up in scans compared to FFG233 in people with solid tumors
2025-523665-24-00Patients with metastatic PDAC, NSCLC, HR+/HER2- ductal and …
Novartis Pharma AG
Neoplasms
Denmark
10/06/2026
Phase III
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
2025-522818-23-00Small Cell Lung Cancer (SCLC)
DrugsZL-1310·Topotecan
Zai Lab (US) LLC
Neoplasms
Belgium, Czechia, Germany, Denmark, Greece, Netherlands, Poland, Spain, Austria, Italy, France
08/06/2026
Phase II
An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) in combination with transoral robotic surgery for oropharyngeal squamous cell carcinoma and neck dissection surgery for oral squamous cell carcinoma with regional lymph node metastases
2025-522845-23-00Oral Squamous Cell Carcinoma with neck metastases, Orophary…
Rigshospitalet
Neoplasms
Denmark
08/06/2026
Phase IV
Measles-mumps-rubella vaccine (MMR) at 6 months of age: Long-term follow-up
2026-526160-21-00Prevention of measles, mumps, and rubella by vaccination
Rigshospitalet
Virus Diseases
Denmark
08/06/2026
Phase I
A study to learn more about how safe BAY 3771249 is and how well it works in people with advanced or metastatic colorectal cancer that has a KRAS G12D mutation
2025-523648-11-00adenocarcinoma of the colon or rectum
Bayer Consumer Care AG
Neoplasms
Finland, Spain, Sweden, Italy, Denmark, Netherlands, Belgium
08/06/2026
Phase I/II
KontRASt-R: An open-label, multi-center, rollover study for participants who have been previously enrolled into a Novartis-sponsored opnurasib (JDQ443) study and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments
2025-523537-26-00Locally advanced or metastatic KRAS G12C-mutated non-small …
Novartis Pharma AG
Neoplasms
Spain, Italy, France, Denmark, Belgium
08/06/2026
Phase III
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
2025-524894-17-00Neovascular age-related macular degeneration (NVAMD)
Eyebiotech Limited
Eye Diseases
Austria, Slovakia, Portugal, Czechia, Hungary, Spain, France, Denmark, Italy, Croatia
05/06/2026
Phase IV
Pulmonary Embolism & Anticoagulation Evaluation in Cancer Patient - PEACE
2025-524110-28-00Incidental Subsegmental Pulmonary Embolism in cancer patien…
DrugsDalteparin·Tinzaparin·Edoxaban·Enoxaparin
Region Hovedstaden
Cardiovascular Diseases
Denmark
04/06/2026
Phase III
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS
2025-522434-32-00Hemophilia A Without Inhibitors
F. Hoffmann-La Roche AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France, Austria, Poland, Netherlands, Spain, Denmark, Italy, Germany, Hungary
01/06/2026
Phase III
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A
2025-522435-33-00Hemophilia A
F. Hoffmann-La Roche AG
Hemic and Lymphatic Diseases
Hungary, Spain, Ireland, Poland, Austria, Germany, Denmark, Belgium, Netherlands, Italy, France
01/06/2026
Phase III
COPE-CP: The effect of Celecoxib on pain, quality of life, use of opioids, and inflammation in patients suffering from chronic pancreatitis: a multicenter randomized placebo-controlled, double-blinded clinical trial
2025-522956-25-00Chronic pancreatitis
DrugCelecoxib
Odense University Hospital
Digestive System Diseases
Denmark
29/05/2026
Phase II
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis
2025-523400-72-00Cystic fibrosis
Vertex Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Sweden, Germany, Italy, Belgium, Czechia, Ireland, Portugal, Netherlands, France, Denmark
29/05/2026
Phase IV
A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza® / Zemaira® Weekly Intravenous Infusions Administered over 3 Years as Longterm Maintenance Therapy in Adult Subjects with Emphysema Related to Alpha1 Antitrypsin Deficiency
2025-522964-33-00Alpha1-proteinase inhibitor deficiency, Alpha1 antitrypsin …
CSL Behring LLC
Respiratory Tract Diseases
Denmark
28/05/2026
Phase II
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials
2025-523579-47-00moderate to severe rheumatoid arthritis (RA)
DrugAfimkibart
F. Hoffmann-La Roche AG
Immune System Phenomena
Italy, Spain, Germany, France, Denmark, Poland, Belgium
27/05/2026
Phase III
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
2025-521590-13-00Moderately to Severely Active Crohn’s Disease
Janssen Cilag International
Immune System Diseases
Slovakia, Germany, Denmark, France, Spain, Italy, Netherlands, Belgium, Poland, Sweden, Austria, Czechia, Hungary
27/05/2026
Phase I/II
LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
2025-522339-32-00Neoplasm malignant
DrugIfinatamab Deruxtecan
Merck Sharp & Dohme LLC
Neoplasms
France, Spain, Sweden, Germany, Italy, Belgium, Denmark, Czechia, Hungary, Netherlands, Slovakia
26/05/2026
Phase I
First-in-human study to assess the safety and feasibility of intra-articular administration of allogeneic engineered gingival fibroblasts (aeGF) in participants with knee osteoarthritis.
2026-525604-99-00Knee osteoarthritis
Scarcell Therapeutics
Musculoskeletal Diseases
Denmark
26/05/2026
Phase IV
A randomized, placebo-controlled, blinded, parallel-group clinical trial to assess the efficacy of N-acetylcysteine in adults with acute infections or sepsis and evidence of liver dysfunction: the IMPACT-NAC trial
2026-525895-25-00Acute infection, Sepsis
Region Hovedstaden
Bacterial Infections and Mycoses
Denmark
22/05/2026
Phase I/II
A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours
2025-524620-22-00Neoplasms benign malignant and unspecified (incl. cysts and…
DrugsODM-212·Sotorasib·Ipilimumab·Nivolumab
Orion Corporation
Neoplasms
Finland, Denmark, Spain, France
22/05/2026
Phase II
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease
2025-524367-20-00Adult patients with primary mitochondrial disease
Pharming Technologies B.V.
Metabolism
Belgium, Germany, Czechia, Spain, Denmark, Italy, France
21/05/2026
Phase I
First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors
2025-524165-25-00Neoplasms
Glaxosmithkline Research & Development Limited
Neoplasms
Spain, Denmark, Finland, France
21/05/2026
Phase II
PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases
2025-523425-17-00Proteinuric kidney diseases
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Nutritional and Metabolic Diseases
Portugal, Greece, Italy, Poland, Estonia, Slovakia, Sweden, Denmark, Belgium, Norway, Romania, France, Spain, Germany, Netherlands, Croatia
19/05/2026
Phase III
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
2025-523735-19-00Metastatic Microsatellite Stable Colorectal Cancer
DrugsINCA33890·Calcium folinate·Fluorouracil·Oxaliplatin
Incyte Corp.
Neoplasms
Poland, France, Denmark, Norway, Spain, Germany, Belgium, Netherlands, Austria, Italy
19/05/2026
Phase II
TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)
2025-522431-34-00Advanced pancreatic cancer
DrugsPemigatinib·Vismodegib·Larotrectinib·Erlotinib
Region Hovedstaden
Neoplasms
Denmark
18/05/2026
Phase II
A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification
2024-518871-74-00Locally Advanced or Metastatic Solid Tumours that harbour M…
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, France, Denmark
18/05/2026
Phase III
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
2025-524316-11-00Primary Progressive Multiple Sclerosis (PPMS)
DrugOrelabrutinib
Zenas Biopharma (USA) LLC
Nervous System Diseases
Italy, Finland, Bulgaria, Greece, Belgium, Estonia, Portugal, Spain, Germany, France, Czechia, Slovakia, Romania, Croatia, Poland, Austria, Netherlands, Denmark, Sweden, Hungary
18/05/2026
Phase I/II
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors
2026-525248-13-00Advanced Solid Tumors
Eikon Therapeutics Inc.
Neoplasms
France, Spain, Norway, Italy, Germany, Austria, Poland, Finland, Belgium, Denmark, Portugal
15/05/2026
Phase III
A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas.
2025-523869-22-00advanced or metastatic extrapulmonary neuroendocrine carcin…
DrugsObrixtamig·Tocilizumab·Carboplatin
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Portugal, Spain, Poland, Sweden, Italy, Czechia, France, Netherlands, Finland, Denmark, Austria, Germany, Belgium, Norway
13/05/2026
Phase II
SCARFREE-001: A Phase 2 Dose-Finding and Proof-of-Concept Study of Intradermal Verteporfin for Scar Prevention in Open and Closed Surgical Wounds
2025-525083-14-00Scar formation following surgical wounds
DrugVerteporfin
Odense University Hospital
Therapeutics
Denmark
13/05/2026
Phase I
A research study to see how NNC0487-0111 affects the body’s energy use after a weight loss in adults living with obesity, compared to a low-calorie diet or placebo
2025-522744-40-00Obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands, Denmark
11/05/2026
Phase III
The GranStone Trial - Prevention of Kidney Stones due to Paraffin Oil Induced Granuloma
2026-525608-85-00Paraffin Oil Induced Granulomatous Disease
DrugsLosartan·Dapagliflozin
Region Hovedstaden
Musculoskeletal Diseases
Denmark
11/05/2026
Phase I
A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD)
2025-520631-17-00Huntington’s Disease Gene Expansion Carriers
F. Hoffmann-La Roche AG
Nervous System Diseases
Italy, Poland, Denmark, Germany, Portugal, Spain
11/05/2026
Phase III
J5E-MC-JZXB - FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
2025-522255-25-00Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neop…
Eli Lilly & Co.
Neoplasms
Netherlands, Hungary, France, Austria, Poland, Italy, Denmark, Romania, Greece, Norway, Czechia, Belgium, Spain, Ireland, Germany
11/05/2026
Phase III
A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies
2025-522983-33-00Chronic rhinosinusitis with nasal polyps
DrugItepekimab
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Germany, Netherlands, Portugal, Denmark, Sweden, Finland, France, Spain, Austria, Italy, Hungary, Romania, Belgium, Czechia, Poland
11/05/2026
Phase II
Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients with Stage I-III dMMR Colon Cancer: A National, Multicentre, Personalised, Phase II Study (RESET C2)
2026-525214-62-00Localised dMMR Colon Cancer
DrugPembrolizumab
Region Sjaelland
Neoplasms
Denmark
07/05/2026
Phase IV
Colchicine Assessment of Low-grade Inflammation and Biomarker Response in Atherosclerosis with Targeted Evaluation
2026-525547-32-01Ischemic Heart Disease, Coronary Artery Disease, Chronic Co…
DrugColchicine
Region Hovedstaden
Cardiovascular Diseases
Denmark
06/05/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
2025-523552-31-00Systemic Lupus Erythematosus
Janssen Cilag International
Immune System Diseases
Denmark, Hungary, Portugal, Italy, Norway, Greece, Slovakia, Czechia, France, Poland, Bulgaria, Germany, Spain, Romania, Finland
05/05/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with obesity (AMAZE 1)
2024-520440-42-00Obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Denmark, France, Germany, Belgium
04/05/2026
Phase III
A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK-034)
2024-516993-31-00Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Neoplasms
Denmark, Spain, Netherlands, Germany, France, Czechia, Poland, Italy, Greece
04/05/2026
Phase III
An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.
2024-520218-23-00Pulmonary Arterial Hypertension
Inhibikase Therapeutics Inc.
Cardiovascular Diseases
Spain, Poland, Italy, Belgium, Latvia, Denmark, Czechia, Germany, France, Netherlands, Portugal, Ireland, Austria, Greece, Lithuania
28/04/2026
Phase III
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
2025-524160-38-00Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dM…
Merck Sharp & Dohme LLC
Neoplasms
Czechia, Spain, Poland, Belgium, Finland, Germany, France, Netherlands, Hungary, Denmark
28/04/2026
Phase III
A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1
2025-522957-20-00Myotonic Dystrophy Type 1
Dyne Therapeutics Inc.
Musculoskeletal Diseases
Netherlands, Spain, Italy, Denmark, Germany, Belgium, France
28/04/2026
Phase III
Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity
2023-509176-42-00Obesity and T2D
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Slovakia, Austria, Spain, Romania, Portugal, Italy, Denmark, Belgium, Sweden, Poland, Netherlands, Croatia, Hungary, Bulgaria
28/04/2026
Phase III
A randomized, open-label, Phase III trial to assess the efficacy and safety of BupiZenge compared to lidocaine for pain associated with oral mucositis in head and neck cancer
2025-524386-24-00Head and neck cancer, Oral mucositis
OncoZenge AB
Anesthesia and Analgesia
Germany, Denmark, Norway, Sweden
28/04/2026
Phase III
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102)
2023-508047-40-00Ovarian cancer
Merck Sharp & Dohme LLC
Neoplasms
Norway, Ireland, Spain, Greece, France, Poland, Denmark, Austria, Hungary, Belgium, Czechia, Finland, Germany, Italy, Sweden
28/04/2026
Phase III
Efficacy and safety of NNC0487-0111s.c once weekly in participants with obesity who have reached target dose during run-in period (AMAZE12).
2025-523804-62-00Obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Belgium, Germany, Bulgaria, France, Spain, Denmark, Italy, Netherlands
27/04/2026
Phase IV
A Study to Evaluate Mirikizumab Concentrations in Breast Milk Following Administration of Mirikizumab by Subcutaneous Injection in Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
2025-522362-78-00severely active ulcerative colitis (US) and CD (Crohn’s dis…
DrugMirikizumab
Eli Lilly & Co.
Immune System Diseases
Spain, Denmark, Germany, Italy, Poland
27/04/2026
Phase II
Methylphenidate for Early Awakening in Coma (MEAWAKE)
2025-524937-19-00Coma due to acute brain injury
DrugMethylphenidate
Rigshospitalet
Nervous System Diseases
Austria, Denmark, Germany, France
27/04/2026
Phase I/II
Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer
2025-523972-21-00Extensive-Stage Small Cell Lung Cancer
Fortvita Biologics (USA) Inc.
Respiratory Tract Diseases
Poland, Denmark, Spain
27/04/2026
Phase I/II
A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
2025-522019-40-00relapsed or refractory BCR::ABL1-positive (Philadelphia pos…
DrugsAsciminib·Hydrocortisone·Blinatumomab·Cytarabine
Novartis Pharma AG
Neoplasms
Italy, Spain, Germany, Netherlands, France, Denmark, Czechia
27/04/2026
Phase IV
Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure (INFUSE-AHF)
2025-523589-26-00Acute heart failure with volume overload
Region Midtjylland
Cardiovascular Diseases
Denmark
24/04/2026
Phase I/II
A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
2025-523474-16-00Malignancies with Documented KRAS, BRAF and Other Selected …
Institut De Recherches Internationales Servier IRIS
Neoplasms
France, Spain, Denmark, Italy
21/04/2026
Phase III
J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.
2025-522855-25-00Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Ne…
DrugsEnfortumab Vedotin·Pembrolizumab
Eli Lilly & Co.
Neoplasms
Italy, Poland, Denmark, Czechia, France, Hungary, Germany, Netherlands, Spain
20/04/2026
Phase IV
Impact of treatment with TransCon PTH on Quality of Life, cognitive function, brain structure, and cerebral capillary bloodflow in patients with hypoparathyroidism
2025-523930-14-00Hypoparathyroidism
Region Midtjylland
Hormonal diseases
Denmark
20/04/2026
Phase III
Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).
2025-523717-29-00HFpEF or HFmrEF and obesity
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Greece, Bulgaria, Italy, Netherlands, Spain, Poland, Czechia, Germany, France
17/04/2026
Phase I/II
An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors
2025-521911-38-00Advanced HR+/HER- breast cancer
DrugsLeuprorelin Acetate·Goserelin·Letrozole·Fulvestrant
Novartis Pharma AG
Neoplasms
Italy, Germany, France, Czechia, Denmark, Spain
16/04/2026
Phase I/II
A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.
2025-522318-21-00Neoplasms, Colorectal
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Denmark, Spain, Sweden, Netherlands, France
14/04/2026
Phase II
Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).
2025-522692-29-00Subacute Moderate to Severe Traumatic Brain Injury (TBI)
DrugCenegermin
Dompe' Farmaceutici S.p.A.
Nervous System Diseases
Italy, Denmark, Finland, France, Germany, Spain, Sweden, Poland
14/04/2026
Phase III
Prevention of chronic headache with anti-CGRP antibody treatment in patients with idiopathic intracranial hypertension
2025-524822-16-00Idiopathic intracranial hypertension
Rigshospitalet
Nervous System Diseases
Denmark
13/04/2026
Phase II
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients with Primary Knee Osteoarthritis
2025-524668-39-00Knee Osteoarthritis
Enlivex Therapeutics Ltd.
Musculoskeletal Diseases
Denmark, Poland
13/04/2026
Phase III
A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with type 2 inflammation.
2025-521108-23-00Chronic Obstructive Pulmonary Disease
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Germany, Belgium, Netherlands, Denmark, Spain, Greece, Poland, Hungary, France, Italy, Bulgaria, Romania
07/04/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 5)
2024-520444-42-00Overweight or obesity, and knee osteoarthritis
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Italy, Greece, Spain, Bulgaria, Denmark, Poland
07/04/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 6)
2024-520445-23-00Overweight or obesity, and knee osteoarthritis
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Poland, Spain, Bulgaria, Italy, Denmark
07/04/2026
Phase II
The NOVA-NOA Trial A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia
2025-524774-42-00Male Infertility
Herlev Hospital
Male Urogenital Diseases
Denmark
07/04/2026
Phase III
J3R-MC-YDAN - A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4) J3R-MC-YOA1: Intervention-Specific Appendix 1 (ISA1) for Eloralintide in Participants with Osteoarthritis Knee Pain J3R-MC-YOA2: Intervention-Specific Appendix 2 (ISA2) for Eloralintide in Participants with Osteoarthritis Knee Pain
2025-523768-19-00Osteoarthritis, Overweight or Obesity
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Denmark, Belgium, Germany, Czechia
02/04/2026
Phase I
Rituximab for Treatment of Checkpoint Inhibitor Induced Immune Related Adverse Events
2026-525728-18-00All CTCAE (v. 6.0) grade 2-4 immune-related adverse events
Region Hovedstaden
Immune System Diseases
Denmark
30/03/2026
Phase II
A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder
2025-524163-21-00Cannabis dependence (Cannabis Use Disorder or CUD)
Region Hovedstaden
Behavior and Behavior Mechanisms
Denmark
30/03/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure (AMAZE 3)
2024-520442-36-00Overweight or obesity, and obstructive sleep apnoea not tre…
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Denmark, Poland, Spain, Germany
30/03/2026
Phase IV
Evidence based empirical antibiotic treatment for urinary tract infections requiring hospitalisation - TRI-AB trial
2024-520251-24-00Complicated urinary tract infections (cUTI) requiring hospi…
Odense University Hospital
Bacterial Infections and Mycoses
Denmark
27/03/2026
Phase III
Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
2025-520466-22-00Advanced Platinum-resistant Epithelial Ovarian Cancer
AstraZeneca AB
Pathological Conditions, Signs and Symptoms
Ireland, Greece, Czechia, France, Sweden, Belgium, Denmark, Spain, Italy, Germany
27/03/2026
Phase III
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator’s Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
2024-519818-31-01Endometrial Cancer Advanced, Recurrent, Metastatic, or Prim…
DrugsDoxorubicin·Paclitaxel
Genmab A/S
Neoplasms
Poland, Denmark, Finland, Lithuania, France, Germany, Spain, Belgium, Greece, Norway, Italy
26/03/2026
Phase I/II
The headache- and migraine-inducing effects of pitolisant in women with migraine without aura
2026-525521-20-00Migraine without aura
DrugsSumatriptan·Pitolisant·Ibuprofen
Syddansk Universitet (University of Southern Denmark)
Nervous System Diseases
Denmark
26/03/2026
Phase III
C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
2025-523521-18-00Metastatic Colorectal Cancer
DrugsPF-08634404·Calcium folinate·Fluorouracil·Oxaliplatin
Pfizer Inc.
Neoplasms
Spain, Belgium, France, Italy, Netherlands, Germany, Poland, Denmark
23/03/2026
Phase I
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
2024-519862-33-01Platinum-resistant ovarian cancer (PROC), Advanced renal ce…
Oncusp Therapeutics Inc.
Neoplasms
Denmark, Spain
23/03/2026
Phase II
A randomized, double blind, placebo-controlled, phase II, multicentre trial to explore the efficacy and safety of oral AP1189 tablets administered at the dose 100 mg/day for 12 weeks in patients diagnosed with polymyalgia rheumatica and in remission on glucocorticoid
2026-525343-33-00Polymyalgia rheumatica
DrugAP1189
Synact Pharma ApS
Musculoskeletal Diseases
Denmark
19/03/2026
Phase II
J6E-MC-KWAN: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis
2025-522338-30-00Ulcerative Colitis
Eli Lilly & Co.
Digestive System Diseases
Hungary, Spain, Denmark, Netherlands, Poland, Romania, Germany, Italy, Austria
18/03/2026
Phase III
A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2
2024-513445-37-00previously untreated RT, irrespective of risk factors and d…
DrugsEpcoritamab·Pirtobrutinib·Prednisolone·Vincristine
University Of Cologne
Neoplasms
Austria, Germany, Denmark, Ireland, Netherlands, Italy
18/03/2026
Phase III
A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants
2025-522191-86-00Focal segmental glomerulosclerosis
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Female Urogenital Diseases and Pregnancy Complications
Germany, Croatia, Poland, Sweden, Portugal, Netherlands, Italy, Denmark, Slovakia, Spain, Norway, Romania, Belgium, Greece, France
17/03/2026
Phase IV
PREDICTION OF COMPLICATIONS IN PATIENTS UNDERGOING SURGICAL TREATMENT OF HEPATIC TUMORS
2025-524477-17-00Hepatic tumor, Hepatic tumor(s)
Rigshospitalet
Neoplasms
Denmark
17/03/2026
Phase I/II
Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)
2024-516896-34-00progressive/relapsed/refractory pediatric low-grade glioma …
DrugTovorafenib
Universitaetsklinikum Heidelberg AöR
Nervous System Diseases
Denmark, Czechia, Austria, Sweden, Germany
17/03/2026
Phase III
A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 (EMBARQ-CSU LTE)
2025-522878-36-00Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics Inc.
Skin and Connective Tissue Diseases
Croatia, France, Netherlands, Bulgaria, Portugal, Slovakia, Hungary, Italy, Greece, Germany, Czechia, Lithuania, Spain, Belgium, Denmark, Poland
16/03/2026
Phase IV
The POST-PRANDIAL HYPO-AVOID STUDY Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced Hypoglycemia in People with Type 1 Diabetes
2025-523996-45-00Type 1 Diabetes Mellitus
Steno Diabetes Center Copenhagen
Hormonal diseases
Denmark
16/03/2026
Phase I
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study
2024-512515-45-01Non-Small Cell Lung Cancer
Theras Inc.
Neoplasms
Spain, Denmark
12/03/2026
Phase II
A randomized placebo-controlled double-blind trial phase II two-arm study to investigate infarct growth over 72 hours assessed with diffusion weighted imaging on MRI after treatment with intravenous tocilizumab or placebo in patients above 18 years of age with acute ischemic stroke undergoing endovascular thrombectomy.
2025-521269-28-00Acute ischemic stroke
DrugTocilizumab
Oslo University Hospital HF
Nervous System Diseases
Norway, Denmark
12/03/2026
Phase I
Safety and Preliminary Efficacy of CTX112 in Adult Participants with Relapsed/Refractory Hematologic Autoimmune Disease
2025-523845-90-00Relapsed/Refractory Hematologic Autoimmune Disease
CRISPR Therapeutics AG
Hemic and Lymphatic Diseases
Spain, Germany, France, Denmark, Italy, Netherlands
12/03/2026
Phase III
Prehospital pulse-dose glucocorticoid in patients with STEMI – the PULSE-MI 2 trial
2025-524320-21-00ST-segment Elevation Myocardial Infarction
Rigshospitalet
Cardiovascular Diseases
Denmark
11/03/2026
Phase I/II
HOVON 178 WM: A prospective phase I/II trial of epcoritamab in patients with relapsed or refractory Waldenstrom’s macroglobulinemia
2025-522295-91-00relapsed or refractory Waldenstrom’s macroglobulinemia
DrugEpcoritamab
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Neoplasms
Denmark, Belgium, Netherlands
10/03/2026
Phase II
SGL-TX-PTDM: SGLT2i effect on PTDM development and kidney allograft function in kidney transplant recipients: A randomized, double-blind, placebo controlled, national multicenter trial
2024-518774-14-00Kidney transplant recipients
DrugDapagliflozin
Odense University Hospital
Not possible to specify
Denmark
09/03/2026
Phase IV
Luteal phase support following letrozole treatment in women undergoing intrauterine insemination: a multicenter randomized trial
2025-524327-53-00Infertility
Region Midtjylland
Not possible to specify
Denmark
09/03/2026
Phase I/II
Allogeneic adipose tissue-derived Mesenchymal stromal cells for the treatment of chronic-active antibody mediated rejection in Kidney transplant recipients
2024-510723-18-00Chronic active antibody mediated rejection
Region Midtjylland
Immune System Diseases
Denmark
09/03/2026
Phase I
Understanding the effect of CagriSema, cagrilintide, and semaglutide on muscle health
2025-522920-28-00Obesity, CCI, CCI
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Denmark
06/03/2026
Phase II
Up-titration of sulfonylurea (SU) in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SUUP)
2025-524679-22-00Maturity-onset diabetes of the young type 3 (HNF1A-MODY), M…
Steno Diabetes Center Copenhagen
Hormonal diseases
Denmark
04/03/2026
Phase IV
A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or Above
2025-524944-37-00Herpes Zoster
Gentofte Hospital, GlaxoSmithKline Biologicals
Skin and Connective Tissue Diseases
Denmark
04/03/2026
Phase III
A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis
2025-521546-23-00Secondary progressive multiple sclerosis
Novartis Pharma AG
Nervous System Diseases
Denmark, Slovenia, Netherlands, Portugal, Ireland, Sweden, Croatia, Greece, Germany, Latvia, Czechia, Spain, Romania, Belgium, Austria, Lithuania, Slovakia, Poland, Estonia, Bulgaria, France, Italy, Hungary, Finland, Norway
03/03/2026
Phase IV
Impact of Early Thyroid Hormone Replacement on Kidney Function and Health-Related Quality of Life in Patients at Risk of Postoperative Hypothyroidism after Hemithyroidectomy: A Randomised Controlled Trial
2025-524175-23-00Hypothyroidism, Incident Kidney Dysfunction, Chronic Kidney…
Region Midtjylland
Otorhinolaryngologic Diseases
Denmark
03/03/2026
Phase II
COMPARISON OF ZINC ACETATE DOSE REGIMENS (GALZIN VS. ET-700) FOR THE TREATMENT OF WILSON DISEASE: A PHARMACODYNAMIC 64CUCL2 PET/CT STUDY IN HEALTHY PARTICIPANTS
2025-523372-24-00Wilson's Disease
Region Midtjylland
Nutritional and Metabolic Diseases
Denmark
02/03/2026
Phase II
An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301
2025-522896-27-00Asthma
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Poland, Italy, Belgium, Sweden, Hungary, France, Germany, Spain, Denmark
02/03/2026
Phase I
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
2025-524334-26-01Endometrial cancer (EC), Advanced or metastatic breast canc…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Denmark
26/02/2026
Phase I
A Pilot, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of a Single Intra-articular Injection of CNTX-0066 in Participants with Chronic, Moderate-to-Severe Osteoarthritis Knee Pain
2025-523737-26-00Osteoarthritis of the knee
Centrexion Therapeutics Corp.
Musculoskeletal Diseases
Denmark
24/02/2026
Phase I
OV-PRIME-R (Oncolytic Virotherapy to enhance PReoperative IMmunotherapy Efficacy in patients with proficient mismatch repair (pMMR) Rectal cancer
2025-524375-23-00Rectal cancer with proficient mismatch repair (pMMR)
Region Hovedstaden
Neoplasms
Denmark
23/02/2026
Phase III
A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients
2025-521521-33-00Kidney transplant rejection
DrugsFrexalimab·Tacrolimus
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany, Hungary, Italy, Belgium, Czechia, Finland, Spain, Austria, Sweden, France, Denmark, Netherlands
23/02/2026
Phase I
A Phase 1 Study of IM-1021 in Participants with Advanced Cancer
2025-523160-20-00Advanced B-cell lymphomas, Advanced solid tumors
Immunome Inc.
Neoplasms
France, Spain, Denmark, Italy
16/02/2026
Phase II
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
2025-521390-14-00Acute Myeloid Leukemia
DrugsRevumenib·Cytarabine·Fludarabine
Pediatric Research International GmbH
Neoplasms
Denmark, Italy, Czechia, Sweden, Poland, Netherlands, Germany, Austria
16/02/2026
Phase I
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
2025-521702-18-00Locally advanced unresectable or metastatic soft tissue sar…
Novartis Pharma AG
Neoplasms
Germany, Portugal, France, Spain, Denmark
16/02/2026
Phase II
A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides difficile Infection in Individuals 18 Years of Age and Above
2025-521416-19-00Recurrence of Clostridioides difficile Infection
AstraZeneca AB
Bacterial Infections and Mycoses
Greece, Spain, France, Germany, Italy, Hungary, Denmark, Sweden
16/02/2026
Phase III
Nordic PREdnisolon for VEstibular NeuriTis Study – an investigator-driven, triple blind, placebo controlled randomized trial
2025-522399-10-00Vestibular neuritis
Region Vaesterbotten, Umea University
Nervous System Diseases
Sweden, Denmark, Norway
11/02/2026
Phase III
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
2025-520805-10-00Chronic inflammatory demyelinating polyneuropathy (CIDP)
DrugEmpasiprubart
Argenx
Nervous System Diseases
Czechia, Denmark, Poland, Slovenia, Netherlands, Austria, Estonia, Slovakia, Hungary, Finland, Bulgaria, France, Italy, Greece, Romania
10/02/2026
Phase II
A Phase 2 randomized, double-blind, placebo-controlled study to investigate efficacy, safety, immunogenicity, and pharmacokinetics, of GSK3862995B in participants with bronchiectasis
2025-522892-27-00Bronchiectasis
GSK PLC
Respiratory Tract Diseases
Denmark, France, Spain, Italy, Germany, Poland
09/02/2026
Phase I
Neoadjuvant nivolumab and ipilimumab for patients with high-risk uveal melanoma
2025-524953-15-00Uveal melanoma
Region Hovedstaden
Eye Diseases
Denmark
04/02/2026
Phase III
ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
2025-522960-34-00Hypertension, Established cardiovascular disease, High card…
Alnylam Pharmaceuticals Inc.
Cardiovascular Diseases
Belgium, Hungary, Czechia, Austria, Germany, France, Greece, Spain, Romania, Netherlands, Italy, Poland, Slovakia, Sweden, Portugal, Denmark, Bulgaria
03/02/2026
Phase II
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D)
2025-521560-36-00Type 1 Diabetes
Sab Biotherapeutics Inc.
Nutritional and Metabolic Diseases
Austria, Germany, Poland, Italy, Denmark, Spain, Belgium, Finland, France, Lithuania, Slovenia
02/02/2026
Phase III
A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).
2025-522553-19-00Symptomatic genetic and familial dilated cardiomyopathy.
Kardigan Inc.
Cardiovascular Diseases
Spain, Denmark, Belgium, Hungary, Italy, Poland, France, Sweden, Netherlands
30/01/2026
Phase III
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OptimUM-10)
2025-522387-32-00Uveal Melanoma
Ideaya Biosciences Inc.
Eye Diseases
France, Spain, Poland, Italy, Czechia, Belgium, Austria, Netherlands, Denmark, Germany
29/01/2026
Phase III
An Open-label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Weekly Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Patients with Alpha1-Antitrypsin Deficiency Compared to Corresponding Standard 60 mg/kg/week and 120 mg/kg/week Doses of Intravenous Alpha1-Proteinase Inhibitor (5%)
2025-522792-29-00Alpha-1 Antitrypsin Deficiency
DrugIVIG
Grifols Therapeutics LLC
Respiratory Tract Diseases
Poland, Denmark, Netherlands, Ireland, Sweden, Spain, Portugal, Germany, France
27/01/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallelgroup Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
2025-521558-40-00Pulmonary Hypertension Associated with Interstitial Lung Di…
DrugTreprostinil Palmitil
Insmed Inc.
Respiratory Tract Diseases
Portugal, Italy, Czechia, Poland, Denmark, Greece, Germany, Romania, Spain, France, Belgium, Austria
26/01/2026
Phase III
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations
2025-521284-12-00Non-small cell lung cancer
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Austria, Portugal, Netherlands, Greece, Belgium, Spain, Germany, France, Romania, Sweden, Italy, Denmark
19/01/2026
Phase II
A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA)
2025-521606-18-00Ovarian Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, Czechia, France, Belgium, Denmark
19/01/2026
Phase III
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PRAGMATYK)
2023-503766-24-00Moderate to Severe Plaque Psoriasis
DrugsUstekinumab·Deucravacitinib
Bristol-Myers Squibb Services Unlimited Company
Immune System Diseases
Romania, Bulgaria, Germany, Spain, Czechia, France, Hungary, Italy, Sweden, Poland, Denmark, Belgium
19/01/2026
Phase I
A study to determine the safety and effect of antibodies against hepatitis D (the SAMBA-D study)
2025-522125-36-00Chronic hepatitis D infection
Region Midtjylland
Virus Diseases
Germany, Denmark
19/01/2026
Phase III
Melatonin versus placebo for bipolar disorder - a double blinded randomised controlled trial (The M-bipolar RCT)
2025-523549-92-00Bipolar disorder
Region Hovedstaden
Mental Disorders
Denmark
16/01/2026
Phase I
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
2025-523101-15-00Relapsed or Refractory Acute Myeloid Leukemia or Higher-Ris…
Genmab A/S
Neoplasms
Denmark, Spain
16/01/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals with Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
2025-521845-26-00BP-I mania or mania with mixed features
DrugKarXT
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Romania, Poland, France, Italy, Denmark, Bulgaria
15/01/2026
Phase III
HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study
2025-522767-15-00Acute Myeloid Leukemia
DrugBleximenib
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Neoplasms
Belgium, Netherlands, Germany, Austria, Denmark, Estonia, Finland, Ireland, Italy, Lithuania, Spain, Sweden, Norway, Poland
15/01/2026
Phase III
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)
2025-521514-26-00Persistent, Recurrent, or Newly Diagnosed Metastatic Cervic…
Merck Sharp & Dohme LLC
Neoplasms
Greece, Ireland, France, Belgium, Czechia, Hungary, Austria, Spain, Sweden, Germany, Poland, Denmark, Italy
14/01/2026
Phase II
A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants with Sepsis-associated Acute Kidney Injury (SERENIA)
2025-522232-13-00Sepsis-associated acute kidney injury (AKI)
DrugAZD4144
AstraZeneca AB
Not possible to specify
Germany, France, Spain, Italy, Belgium, Czechia, Greece, Denmark, Hungary
14/01/2026
Phase II
Open-label proof-of-concept trial of topical delgocitinib in patients with facial vitiligo
2025-523635-19-00Vitiligo
Gentofte Hospital
Skin and Connective Tissue Diseases
Denmark
12/01/2026
Phase I/II
Inhibiting the anti-apoptotic factor, BCL-2, at the time of ART initiation to promote apoptosis of HIV-infected cells and restrict the seeding of the HIV reservoir: An investigator-initiated randomised, controlled, open-label clinical trial (The INITIATE Study)
2025-521841-26-00HIV-1 infection
Region Midtjylland
Virus Diseases
Denmark, Spain
02/01/2026
Phase III
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early-Stage Parkinson’s Disease
2025-522683-32-00Early-Stage Parkinson’s Disease (PD)
F. Hoffmann-La Roche AG
Nervous System Diseases
France, Austria, Portugal, Netherlands, Poland, Germany, Spain, Denmark, Italy
23/12/2025
Phase III
A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
2025-521117-88-00Cardiovascular Disease
Amgen Inc.
Cardiovascular Diseases
France, Denmark, Germany, Spain, Italy, Netherlands
22/12/2025
Phase II
Normothermic intraperitoneal chemotherapy (NIPEC) with carboplatin following cytoreductive surgery in elderly and fragile ovarian cancer patients: a feasibility study
2025-522269-30-00Ovarian cancer
Odense University Hospital
Therapeutics
Denmark
22/12/2025
Phase I/II
Open-labelled, single-centre investigation of safety and tolerability of multiple ascending doses of nebulised SS0331 in healthy participants followed by investigation of preliminary efficacy of nebulised SS0331 in airway-infected patients with chronic airway infections
2025-523875-48-00Chronic airway infections
Softox Solutions AS
Virus Diseases
Denmark
19/12/2025
Phase III
A Phase III, randomised, double-blind, placebo-controlled, parallel-group, pivotal trial to assess the efficacy and safety of sonlicromanol in adult subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G variant.
2025-522361-30-00Primary Mitochondrial Disease, Mitochondrial DNA 3243A>G va…
DrugSonlicromanol
Khondrion B.V.
Nervous System Diseases
Italy, Germany, France, Netherlands, Denmark
19/12/2025
Phase III
Contrast Strategy In Fenestrated EndoVascular Aneurysm Repair Randomized Control Trial
2025-521795-58-00Abdominal aortic aneurysm
DrugIohexol
Region Skane
Cardiovascular Diseases
Sweden, Denmark
16/12/2025
Phase I
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors
2025-523165-19-00Advanced, metastatic or unresectable solid tumors
BeOne Medicines I GmbH
Neoplasms
Denmark, France
11/12/2025
Phase III
AALL2131/EsPhALL2022, An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitor with Blinatumomab in Patients with Newly Diagnosed Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
2025-520982-39-00Philadelphia Chromosome Positive or ABL-class Philadelphia …
Universita Degli Studi Di Milano Bicocca
Neoplasms
France, Lithuania, Norway, Finland, Spain, Italy, Czechia, Germany, Hungary, Slovakia, Denmark, Austria, Netherlands
09/12/2025
Phase III
CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM).
2024-518899-31-00Variant or wild-type transthyretin (TTR) amyloid cardiomyop…
Novo Nordisk A/S
Cardiovascular Diseases
Germany, France, Belgium, Italy, Denmark, Netherlands, Spain, Czechia
09/12/2025
Phase III
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020
2023-509392-17-00Relapsed Acute Lymphoblastic Leukemia (ALL)
DrugsIdarubicin·Inotuzumab Ozogamicin·Pegaspargase·Mercaptopurine
Charite Universitaetsmedizin Berlin KöR
Hemic and Lymphatic Diseases
Netherlands, Czechia, Italy, Spain, Denmark, Austria, Norway, Sweden, Germany, France, Finland, Slovenia
09/12/2025
Phase IV
COPD-2VAX: Enhancing Protection Against Respiratory Infections Through AS01-Mediated Innate Immune Activation in High-Risk Patients
2024-519163-18-00Chronic Obstructive Pulmonary Disease (COPD)
Nordsjaellands Hospital
Virus Diseases
Denmark
08/12/2025
Phase I/II
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematologic Malignancies with KMT2Ar, NPM1m, or Other Genotypes Associated with HOX Overexpression
2025-521299-76-00Relapsed or refractory acute leukaemia or Myelodysplastic S…
AstraZeneca AB
Neoplasms
Germany, Italy, Denmark
08/12/2025
Phase II
A Danish, double-blind, randomized placebo-controlled clinical trial evaluating allogeneic adipose tissue derived mesenchymal stromal cell therapy in patients with recently diagnosed non-ischemic heart failure with reduced ejection fraction.
2025-520837-22-00Non-ischemic heart failure with reduced ejection fraction
Cell2Cure ApS
Cardiovascular Diseases
Denmark
08/12/2025
Phase III
A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice-Weekly, Followed by a Long-Term, Open-Label Safety Evaluation in Patients with Short Bowel Syndrome–Intestinal Failure (SBS-IF)
2024-512486-14-00Short Bowel Syndrome
DrugGlepaglutide
Zealand Pharma A/S
Digestive System Diseases
Finland, France, Belgium, Germany, Hungary, Spain, Austria, Netherlands, Italy, Denmark, Czechia, Norway, Poland, Sweden, Estonia
04/12/2025
Phase III
A phase 3, randomized, double-blind, placebo-controlled, multicenter study with open-label extension to evaluate the efficacy and safety of bimekizumab in study participants with palmoplantar pustulosis
2024-520337-80-00Palmoplantar Pustulosis
UCB Biopharma
Immune System Diseases
Czechia, Denmark, Spain, Poland, Germany, Hungary, Italy, France
02/12/2025
Phase I/II
TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer
2025-521880-10-00Metastatic castrate resistant prostate cancer (mCRPC)
Novartis Pharma AG
Neoplasms
Italy, Germany, Poland, France, Denmark, Spain
01/12/2025
Phase III
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038)
2025-521970-33-00​​Pulmonary Arterial Hypertension (PAH)
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Czechia, Germany, Sweden, Greece, Croatia, Belgium, Poland, Spain, Portugal, Italy, Denmark, France, Netherlands
01/12/2025
Phase III
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
2024-520097-36-00Chronic inflammatory demyelinating polyneuropathy (CIDP)
DrugEmpasiprubart
Argenx
Nervous System Diseases
Czechia, Bulgaria, Netherlands, Hungary, Sweden, Slovakia, Slovenia, Greece, Norway, Poland, Italy, Spain, Estonia, Denmark, France, Romania, Portugal, Austria, Germany
01/12/2025
Phase II
A phase 2, multicenter, randomized, placebo-controlled, double-blind study to investigate the safety, pharmacodynamics, and preliminary efficacy of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease.
2025-522146-40-00Late-onset Pompe disease.
Shionogi B.V.
Nutritional and Metabolic Diseases
Belgium, Germany, Denmark, France, Italy, Spain, Netherlands
01/12/2025
Phase III
A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-Paclitaxel and Gemcitabine versus Placebo in Combination With Nab-Paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
2025-522598-12-00Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Czechia, Austria, Belgium, Ireland, Spain, Germany, Romania, Netherlands, Slovakia, Greece, Poland, Italy, Denmark, France, Sweden
28/11/2025
Phase IV
A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness and Safety of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 (DAN-COVID)
2025-523841-82-00SARS-CoV-2 infection
Gentofte Hospital, Moderna Inc.
Virus Diseases
Denmark
26/11/2025
Phase III
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation.
2024-520418-22-00Chronic Obstructive Pulmonary Disease
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Slovakia, Denmark, France, Sweden, Ireland, Belgium, Netherlands, Spain, Croatia, Germany, Poland, Hungary, Norway, Portugal
24/11/2025
Phase III
REVERsal to normoglycemia by Treating PREDIABETES: the REVERT-PREDIABETES trial
2025-522970-35-00Coronary artery disease, Prediabetes
Region Midtjylland
Cardiovascular Diseases
Denmark
23/11/2025
Phase II
A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors
2025-521034-28-00Moderate to Severe Rheumatoid Arthritis (RA)
DrugAfimkibart
F. Hoffmann-La Roche AG
Immune System Phenomena
Italy, Denmark, France, Poland, Germany, Spain, Belgium
23/11/2025
Phase III
C5851005 - PADLINK-005: A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)
2025-521281-97-00Non-Small Cell Lung Cancer (NSCLC)
Pfizer Inc.
Neoplasms
Greece, Italy, Belgium, Slovakia, Czechia, Germany, France, Poland, Denmark, Spain, Netherlands, Sweden, Finland, Bulgaria
17/11/2025
Phase III
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)
2024-518777-34-00B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
DrugsDoxorubicin·Paclitaxel
AstraZeneca AB
Neoplasms
Italy, Netherlands, Lithuania, Finland, Greece, Austria, Belgium, Hungary, Spain, Poland, Czechia, Germany, France, Denmark, Slovenia
17/11/2025
Phase III
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL.
2025-522052-13-00Framework for Optimizing, Refining, and Unifying Management…
DrugsTreosulfan·Thiotepa·Busulfan·Blinatumomab
Ospedale Pediatrico Bambino Gesu
Hemic and Lymphatic Diseases
Germany, Denmark, Finland, Norway, Austria, Italy, Poland, France, Czechia, Belgium, Croatia, Hungary, Lithuania, Sweden, Netherlands, Slovakia
17/11/2025
Phase IV
Enhancing Lung Health in Kids with structural Lung Damage and Malformations: a randomized controlled trial on Azithromycin (AZI) for Airway Infection Prevention
2024-518730-88-00Chronic Atelectasis, Cystic Lung Malformations, Bronchiecta…
DrugAzithromycin
Rigshospitalet
Bacterial Infections and Mycoses
Denmark
14/11/2025
Phase II
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)
2025-521737-91-00Neoplasm malignant with KRAS G12C mutation
Merck Sharp & Dohme LLC
Neoplasms
Norway, Spain, Sweden, Italy, Denmark, France, Poland, Germany, Greece
12/11/2025
Phase III
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor
2025-523083-21-00PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Gr…
Relay Therapeutics Inc.
Neoplasms
Hungary, Spain, Italy, Belgium, Netherlands, Austria, Germany, Greece, Czechia, Denmark, Poland, Bulgaria, Portugal, France, Ireland, Romania
11/11/2025
Phase III
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
2024-517136-21-00Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Neoplasms
Greece, Germany, France, Italy, Croatia, Denmark, Czechia, Austria, Belgium, Ireland, Spain, Poland
10/11/2025
Phase II
A Phase 2, Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of LTG-001 in Patients with Osteoarthritis of the Knee
2025-522755-26-01Osteoarthritis of the knee
Latigo Biotherapeutics Inc.
Musculoskeletal Diseases
Denmark
10/11/2025
Phase I/II
A Phase 1/2a, First-in-human, Open label Study of BMS-986517 as Monotherapy or Combination Therapy in Adult Participants with Advanced Solid Tumors
2025-522203-23-00Advanced Solid Tumors
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Denmark, Spain
07/11/2025
Phase III
Prevention and Treatment of Episodic migraine by Cabergoline Therapy (PROTECT) A randomized, placebo-controlled, double-blind, investigator-initiated trial
2025-522323-10-00Migraine
DrugCabergoline
Region Midtjylland
Nervous System Diseases
Denmark
07/11/2025
Phase II
A phase 2 randomized, double blind, placebo-controlled study to evaluate the safety and efficacy of topical AT-004 1% in the participants with acne vulgaris.
2025-521510-25-00Acne vulgaris
Arctic Therapeutics hf.
Skin and Connective Tissue Diseases
Denmark
07/11/2025
Phase III
A multicenter, phase 3, randomized, placebo-controlled, triple-blind crossover study of candesartan for prevention of chronic cluster headache (Chronic CandClus2)
2025-521529-34-00chronic cluster headache
DrugCandesartan
Helse Bergen HF, St. Olavs Hospital HF
Nervous System Diseases
Norway, Denmark
04/11/2025
Phase III
A phase 3 randomized, placebo-controlled, triple blind parallel-group study of candesartan in adults with episodic cluster headache (Episodic CandClus2)
2025-521470-34-00episodic cluster headache
DrugCandesartan
Helse Bergen HF, St. Olavs Hospital HF
Nervous System Diseases
Denmark, Norway
04/11/2025
Phase III
A Phase III, Multicenter, Randomized, Double blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants with Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)
2024-518008-33-00Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia…
F. Hoffmann-La Roche AG
Nervous System Diseases
Poland, France, Germany, Netherlands, Spain, Italy, Denmark
04/11/2025
Phase III
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants with Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
2024-518006-40-00Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia…
DrugsFlorbetaben·Trontinemab
F. Hoffmann-La Roche AG
Nervous System Diseases
Spain, Poland, Italy, Denmark, France, Germany
04/11/2025
Phase I/II
(22931) A first-in-human study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor, in participants with MTAP-deleted solid tumors.
2025-520623-24-00MTAP-deleted Solid Tumors
Bayer AG
Neoplasms
Belgium, Sweden, Denmark, Italy, Spain, Netherlands, Czechia
04/11/2025
Phase III
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
2025-521012-18-00Facioscapulohumeral Muscular Dystrophy (FSHD)
Avidity Biosciences Inc.
Musculoskeletal Diseases
Italy, France, Germany, Spain, Denmark, Netherlands
04/11/2025
Phase I/II
A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of the oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP inhibitor (PARPi) niraparib in adult participants with solid tumors.
2024-520197-36-00Neoplasms
Glaxosmithkline Research & Development Limited
Neoplasms
Estonia, Czechia, Spain, Romania, Italy, Denmark, Belgium, Greece
03/11/2025
Phase II
A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 years of Age and Older With Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization
2025-523009-14-00Bronchiectasis with chronic pseudomonas aeruginosa coloniza…
AstraZeneca AB
Respiratory Tract Diseases
Netherlands, Italy, Greece, Denmark, Belgium, Spain, France, Germany
31/10/2025
Phase I
European, multicentre, single arm (phase I) trial of autologous skeletal muscle derived cell (ASMDC) microcarrier combination for the treatment of faecal incontinence (FI) in women with obstetric anal sphincter injury.
2023-504282-23-00Faecal incontinence
University College London
Female Urogenital Diseases and Pregnancy Complications
France, Spain, Austria, Denmark
28/10/2025
Phase I
AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors
2025-521707-48-00KRAS Altered Advanced or Metastatic Solid Tumors
Amgen Inc.
Neoplasms
France, Netherlands, Germany, Denmark, Spain, Italy, Belgium
28/10/2025
Phase IV
PROlonged versus Single dose in PEnicillin oral Challenge Testing double-blind parallel randomized placebo cOntrolled tRial – PROSPECTOR-2 Study
2025-520888-41-00Penicillin allergy
Gentofte Hospital, Austin Health
Immune System Diseases
Belgium, Denmark
28/10/2025
Phase II
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2024-517614-14-00Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
Immune System Diseases
Austria, Hungary, Slovenia, Greece, Denmark, Ireland, Finland, Estonia, Spain, Slovakia, Netherlands, Poland, Norway, Italy, Portugal, Belgium, Germany, Romania, Bulgaria
28/10/2025
Phase III
A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2- expressing recurrent endometrial cancer
2023-507525-42-00Endometrial cancer
BioNTech SE
Female Urogenital Diseases and Pregnancy Complications
Denmark, Poland, Italy, Finland, Czechia, Sweden, Greece, Belgium, Norway, Hungary, Germany, Austria, France, Spain, Netherlands
27/10/2025
Phase III
A Phase 3, Multi-Site, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of eRapa to Improve Clinical Outcomes in Participants with Familial Adenomatous Polyposis
2025-522946-37-00Familial adenomatous polyposis (FAP)
Biodexa Limited, Rapamycin Holdings Inc.
Virus Diseases
Denmark, Spain, Germany, Netherlands, Italy
27/10/2025
Phase I
A Study Testing the Investigational Drug XmAb541 in people with Advanced Cancer
2025-521981-90-00Advanced Solid Tumors
Xencor Inc.
Neoplasms
Spain, France, Belgium, Denmark
27/10/2025
Phase III
A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion.
2025-521511-40-00metastatic non-small cell lung cancer
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Greece, Czechia, France, Sweden, Romania, Belgium, Austria, Bulgaria, Italy, Netherlands, Denmark, Germany, Poland, Hungary, Spain
24/10/2025
Phase III
A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)
2024-513676-18-00Transthyretin Amyloidosis
DrugAcoramidis
Eidos Therapeutics Inc.
Cardiovascular Diseases
Germany, Portugal, Netherlands, France, Spain, Italy, Ireland, Belgium, Sweden, Denmark, Greece
22/10/2025
Phase III
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
2024-518365-10-00Previously Untreated Advanced or Metastatic Non-Squamous No…
F. Hoffmann-La Roche AG
Neoplasms
Ireland, Greece, Hungary, Netherlands, France, Denmark, Germany, Poland, Italy, Portugal, Spain, Belgium
21/10/2025
Phase III
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis
2024-515979-35-00Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Nervous System Diseases
Czechia, Greece, Spain, Italy, Denmark, Germany, Romania, Poland, Hungary
20/10/2025
Phase III
EUROpean pragmatic multicenter randomized trial on platelet inhibition and/or lipid lowering treatment in Covert Brain Infarction (CBI)
2025-521452-30-01Covert brain infarction (asymptomatic brain infarctions)
DrugsAcetylsalicylic acid·Rosuvastatin·Atorvastatin·Clopidogrel
Region Midtjylland
Nervous System Diseases
Denmark, Sweden, Norway
17/10/2025
Phase IV
Steroids and/ or Non-steroidal Anti-inflammatory Drugs in the Postoperative Regime After Trabeculectomy. (SNAP)
2025-523957-32-00Medically uncontrolled glaucoma that requires filtration su…
Rigshospitalet
Eye Diseases
Denmark
17/10/2025
Phase III
A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed During or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment. TROPION-Urothelial03 (TU03).
2024-516906-47-00Locally Advanced or Metastatic Urothelial Carcinoma
DrugsDato-DXd·Cisplatin·Carboplatin
Daiichi Sankyo Inc.
Neoplasms
Netherlands, Germany, Norway, Denmark, France, Austria, Italy, Spain, Belgium, Czechia, Greece
15/10/2025
Phase III
TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)
2024-519917-72-00Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloid…
Alnylam Pharmaceuticals Inc.
Cardiovascular Diseases
France, Germany, Italy, Greece, Belgium, Portugal, Netherlands, Austria, Sweden, Denmark, Spain, Czechia, Hungary, Ireland, Romania, Norway, Poland, Slovakia
14/10/2025
Phase I
Early-stage clinical trial investigating the individual and combined effect of two drugs, senicapoc and perampanel, as part of the treatment for newly diagnosed glioblastoma, which is an aggressive brain tumor
2025-522605-37-00Glioblastoma
Region Midtjylland
Neoplasms
Denmark
14/10/2025
Phase III
J2O-MC-EKBG: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event - MOVE-Lp(a)
2025-521067-13-00Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASC…
Eli Lilly & Co.
Cardiovascular Diseases
Italy, Poland, Germany, Austria, Romania, Spain, Czechia, France, Denmark, Greece, Hungary, Slovakia, Belgium, Netherlands
13/10/2025
Phase III
Effects of ziltivekimab versus placebo on coronary atherosclerosis in patients with acute myocardial infarction. A serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study
2024-520364-34-00Acute myocardial infarction
Novo Nordisk A/S, ECRI-trials B.V.
Cardiovascular Diseases
Italy, Netherlands, Austria, Denmark, Spain
13/10/2025
Phase II
Perineural incobotulinumtoxin-A for Complex Regional Pain Syndrome - An open-label feasibility study (PINCom)
2024-519832-17-00Complex Regional Pain Syndrome
Rigshospitalet
Nervous System Diseases
Denmark
13/10/2025
Phase III
A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients with Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX-3)
2025-521785-10-00Glioblastoma
Telix Pharmaceuticals (Innovations) Pty Limited
Neoplasms
Austria, Netherlands, Belgium, Denmark, France, Germany, Spain
13/10/2025
Phase I
A multi-part, adaptive, Phase 1, first time in human study in healthy participants and participants with atopic dermatitis (AD) to assess the safety, tolerability, pharmacokinetics (PK) of single ascending (SAD), multiple ascending doses (MAD) and selected dose of SYX-5219 (AD Participants)
2025-522216-17-00Atopic Dermatitis
Sitryx Therapeutics Limited
Skin and Connective Tissue Diseases
Germany, Bulgaria, Ireland, Denmark
09/10/2025
Phase II
A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)
2024-519278-37-00Systemic Lupus Erythematosus, Lupus Nephritis
Celgene Corp.
Immune System Diseases
France, Spain, Portugal, Germany, Belgium, Poland, Italy, Denmark, Austria
06/10/2025
Phase III
C4951063: An interventional efficacy and safety, Phase 3, double-blind, parallel group study to investigate intermittent prevention of Menstrual Migraine with Rimegepant compared with placebo in women participants 18 to 45 years of age
2024-517121-10-00Menstrual Migraine
Pfizer Inc.
Nervous System Diseases
Netherlands, Italy, Poland, Denmark, Germany, Spain
06/10/2025
Phase III
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00Atherosclerotic cardiovascular disease (ASCVD) and obesity …
Amgen Inc.
Cardiovascular Diseases
Slovakia, Denmark, Portugal, Czechia, Poland, Greece, Bulgaria, France, Spain, Sweden, Finland, Belgium, Romania, Germany, Hungary, Netherlands, Italy, Austria
06/10/2025
Phase II
A Phase 1b/2 Open-Label, Multicenter Study of Zoldonrasib (RMC-9805) with or without Daraxonrasib (RMC-6236), in Combination with Other Anticancer Agents, in Patients with RAS G12D-Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol C
2025-521147-21-00Lung Cancer
DrugsRMC-9805·Cetuximab·Pemetrexed·Cisplatin
Revolution Medicines Inc.
Respiratory Tract Diseases
Germany, Austria, France, Netherlands, Czechia, Greece, Italy, Spain, Denmark
06/10/2025
Phase IV
The DALBA-study Introduction of the antibiotic dalbavancin in orthopaedic surgery – an evaluation of: • Health economic costs • Patient-reported outcomes on quality of life • Local bone and soft tissue concentrations • Effect on the gut microbiome A randomised controlled study of dalbavancin versus standard antibiotic treatment of Gram-positive periprosthetic joint infections.
2025-522088-13-00Periprosthetic joint infection
Region Midtjylland
Bacterial Infections and Mycoses
Denmark
02/10/2025
Phase IV
Heart rate control: Betablockers or Ivabradine therapy before cardiac computed tomography
2025-522741-21-00ischemic heart disease
Region Midtjylland
Cardiovascular Diseases
Denmark
01/10/2025
Phase IV
A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease (AEOLUS)
2025-521268-37-00Respiratory tract diseases
DrugsSalbutamol·Dupilumab
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Netherlands, Hungary, France, Germany, Austria, Spain, Poland, Sweden, Italy, Denmark
29/09/2025
Phase III
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
2025-520766-22-00Myotonic Dystrophy Type 1
Avidity Biosciences Inc.
Musculoskeletal Diseases
France, Denmark, Spain, Italy, Germany, Netherlands
29/09/2025
Phase III
A Phase 3b Extension Study to Evaluate the Long-Term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease
2023-508804-39-00Ulcerative Colitis or Crohn’s Disease
Takeda Development Center Americas Inc.
Digestive System Diseases
Spain, Ireland, Portugal, Poland, Belgium, Netherlands, Bulgaria, Romania, Italy, Denmark
29/09/2025
Phase II
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of SAR444336 in participants with microscopic colitis in clinical remission with budesonide.
2024-519495-83-00Digestive system diseases
Sanofi-Aventis Recherche & Developpement
Digestive System Diseases
Italy, Sweden, Germany, France, Poland, Denmark, Belgium, Hungary
29/09/2025
Phase II
A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination with Somatostatin Analogs in Adult Participants with Acromegaly
2025-521243-20-00Acromegaly
Alexion Pharmaceuticals Inc.
Hormonal diseases
Lithuania, Romania, Denmark, Italy, Hungary, Poland, Netherlands
29/09/2025
Phase II
Clinical Randomised Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation.
2025-521377-14-00Atrial fibrillation
Acesion Pharma ApS
Cardiovascular Diseases
Hungary, Italy, Denmark, Bulgaria, Poland, Netherlands, Germany
29/09/2025
Phase II
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 years) with Non-cystic Fibrosis Bronchiectasis
2024-518821-13-00Non-cystic Fibrosis Bronchiectasis
CSL Behring LLC
Respiratory Tract Diseases
Spain, Belgium, Germany, Greece, Denmark, Netherlands, Hungary, Italy, France, Poland
26/09/2025
Phase III
Obesity and Semaglutide in Type 1 Diabetes Therapy (OBES1TY): A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial
2025-522326-13-00Obesity defined by BMI equal to or higher than 30, Obesity …
Region Hovedstaden
Hormonal diseases
Denmark
26/09/2025
Phase III
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2024-517131-52-00Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymp…
BeOne Medicines AG
Neoplasms
France, Sweden, Czechia, Austria, Belgium, Germany, Denmark, Spain, Netherlands, Italy, Ireland, Poland
26/09/2025
Phase I/II
A phase 1/2, open label, multicenter clinical trial investigating the safety, tolerability, pharmacokinetics, and antineoplastic activity of S095035 (MAT2A inhibitor) as a single agent and in combination in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP
2025-521249-25-00MTAP-deleted advanced or metastatic solid tumors
Institut De Recherches Internationales Servier IRIS
Neoplasms
Denmark, Italy, Germany, Spain, France
26/09/2025
Phase II
The effect of colchicine, on insulin sensitivity in individuals with type 1 diabetes and systemic low-grade inflammation (INS1GHT)
2025-522528-29-00Type 1 diabetes
Gentofte Hospital
Hormonal diseases
Denmark
26/09/2025
Phase III
EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease
2025-521188-11-00cardiovascular disease, hypertension, Type 2 diabetes
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Cardiovascular Diseases
Lithuania, Netherlands, Ireland, Romania, France, Hungary, Finland, Latvia, Austria, Germany, Greece, Italy, Sweden, Denmark, Czechia, Belgium, Slovakia, Croatia, Spain, Norway, Bulgaria, Poland, Portugal
24/09/2025
Phase I
A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants with Advanced Solid Tumors
2024-519622-20-00Advanced Solid Tumors Harboring RAS Mutation(S)
F. Hoffmann-La Roche AG
Neoplasms
Germany, Netherlands, Spain, Denmark, France, Belgium
22/09/2025
Phase II
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 3-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO).
2025-520473-40-00Moderate to Very Severe Chronic Obstructive Pulmonary Disea…
AstraZeneca AB
Respiratory Tract Diseases
Spain, Greece, Bulgaria, Germany, Denmark, Hungary, Italy, Poland
22/09/2025
Phase II
A Phase 2, Open-Label, Multicenter Study of Zoldonrasib(RMC-9805) in Previously Treated Patients with RAS G12DMutant Non-Small Cell Lung Cancer (NSCLC) – Subprotocol D
2025-521681-10-00Lung Cancer
Revolution Medicines Inc.
Respiratory Tract Diseases
Germany, Greece, Netherlands, Czechia, France, Austria, Denmark, Spain, Italy
22/09/2025
Phase I
An exploratory study to investigate the impact on the viral reservoir of adding a broadly neutralizing antibody with or without an attachment inhibitor to an integrase inhibitor-based antiretroviral therapy regimen in adults living with HIV (ENTRANCE)
2025-520629-19-00HIV Infections
Viiv Healthcare UK Limited
Virus Diseases
Netherlands, Spain, Belgium, Denmark
22/09/2025
Phase III
A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)
2025-520554-11-00Cardiovascular Disease
Amgen Inc.
Cardiovascular Diseases
Spain, Hungary, Portugal, Greece, Germany, Italy, Austria, Ireland, Romania, Slovakia, Netherlands, Czechia, Bulgaria, Denmark, France, Poland, Belgium
22/09/2025
Phase III
Remifentanil versus rocuronium for optimizing video laryngoscopy assisted tracheal intubation in patients undergoing general anaesthesia - a multicentre randomised controlled trial The ROCVIDEO trial
2025-521405-40-01Adult patients undergoing tracheal intubation using video l…
Nordsjaellands Hospital
Equipment and Supplies
Denmark, Sweden
22/09/2025
Phase II
Ipilimumab and nivolumab plus temozolomide and capecitabine for patients with chemo-refractory pMMR, MGMT silenced metastatic colorectal cancer: The MAYA2 trial
2025-521941-25-00Colorectal cancer
DrugsTemozolomide·Ipilimumab·Nivolumab·Capecitabine
Odense University Hospital
Neoplasms
Denmark
19/09/2025
Phase II
A Randomized, placebo-controlled, double-blinded Phase 2 Trial of Dapagliflozin for Preventing Treatment-associated Cardiotoxicity in Lymphoma
2025-521205-41-00Diffuse large B-cell lymphoma (all subtypes), any type of l…
Aalborg University Hospital
Neoplasms
Denmark
14/09/2025
Phase IV
Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy (FLEET): A Randomized Controlled Trial
2025-522506-20-00Depression
Region Hovedstaden
Nervous System Diseases
Denmark
09/09/2025
Phase IV
Semaglutide and Finerenone for Kidney and Vascular Protection in CKD
2025-522503-18-00Chronic kidney disease
Region Midtjylland
Pathological Conditions, Signs and Symptoms
Denmark
09/09/2025
Phase II
Repeated Mesenchymal Stem Cell Therapy for Radiation-Induced Hyposalivation and Xerostomia in Head and Neck Cancer Survivors
2025-522559-25-00Xerostomia due to readiotherapy for a head & neck cancer
DrugDopamine
Rigshospitalet
Neoplasms
Denmark
08/09/2025
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease
2024-518296-56-00Crohn’s Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Digestive System Diseases
Spain, Austria, Lithuania, France, Belgium, Germany, Sweden, Czechia, Finland, Croatia, Latvia, Portugal, Netherlands, Italy, Denmark, Slovakia, Romania, Poland, Ireland, Hungary, Greece
03/09/2025
Phase III
A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
2024-519827-16-00Newly Diagnosed Transplant Ineligible Multiple Myeloma Pati…
European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale
Neoplasms
Norway, Denmark, Spain, Sweden, Austria, Netherlands, Greece, Germany, Italy, Belgium, Portugal, Estonia, Croatia, Ireland, Czechia, Finland
01/09/2025
Phase III
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
2024-520050-38-00Extensive stage small cell lung cancer (ES-SCLC). …
DrugsSiltuximab·Mycophenolate Mofetil·Tarlatamab·Infliximab
Amgen Inc.
Neoplasms
Portugal, Germany, Spain, Italy, Denmark, Netherlands, France, Austria, Greece, Belgium, Hungary, Poland, Romania
01/09/2025
Phase III
A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of chronic migraine (MINT-C)
2024-515682-34-00Chronic migraine
Merz Therapeutics GmbH
Nervous System Diseases
Spain, Denmark, France, Germany, Slovakia, Austria, Italy, Poland, Czechia
01/09/2025
Phase III
A phase 3, randomised, multi-center, open label trial to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade Bacillus Calmette-Guerin therapy (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC)
2024-512177-27-01High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-m…
Ferring Pharmaceuticals A/S
Male Urogenital Diseases
Spain, Denmark, Poland, Czechia, France
01/09/2025
Phase III
A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of episodic migraine (MINT-E)
2024-515715-22-00Episodic migraine
Merz Therapeutics GmbH
Nervous System Diseases
Italy, Austria, Poland, Germany, France, Spain, Slovakia, Denmark, Czechia
01/09/2025
Rows per page Showing 1–331 of 331
1
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-europe/country/denmark

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,561 trial records at the last sync on 06 Oct 2026, 03:17 UTC; this register shows the 2,557 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 331 of those trials with a site in Denmark.

How many recently authorised EU trials have a site in Denmark?

331 of the 2,557 most recently authorised trials in this register list a site in Denmark; 153 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase (Denmark), 331 trials
PhaseTrialsShare
Phase III15346.2%
Phase II8024.2%
Phase IV3911.8%
Phase I3510.6%
Phase I/II247.3%

Most active sponsors

Lead sponsors with the most trials (Denmark)
Lead sponsorTrials
Region Hovedstaden26
Region Midtjylland19
AstraZeneca AB16
F. Hoffmann-La Roche AG13
Merck Sharp & Dohme LLC12
Novo Nordisk A/S12
Rigshospitalet11
Odense University Hospital10
Novartis Pharma AG8
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.7
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.